Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD students, we found it difficult to access the research we needed, so we decided to create a new Open Access publisher that levels the playing field for scientists across the world. How? By making research easy to access, and puts the academic needs of the researchers before the business interests of publishers.
We are a community of more than 103,000 authors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the world’s most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too.
To purchase hard copies of this book, please contact the representative in India:
CBS Publishers & Distributors Pvt. Ltd.
www.cbspd.com
|
customercare@cbspd.com
Literature data on the insulinogenic effect of 2-aminobenzimidazole prompted us to investigate its novel derivatives, particularly those containing an additional fused cycle in C1,2-α position, including imidazole, dihydroimidazole, or tetrahydropyrimidine ring. Consensus analysis of the hypoglycemic effect of these compounds performed with IT Microcosm and PASS system revealed that activity is mostly characteristic for N9-2,3-dihydroimidazo[1,2-a]benzimidazole derivatives. Substructural analysis of hypoglycemic activity identified substituents that determine the greatest pharmacological effect. According to the in silico assessment of the ADME properties, RU-254 was nominated as a lead compound due to the most optimal calculated and experimental activity and pharmacokinetic parameters. Preclinical studies have shown that identified compound has a pronounced insulinogenic effect and hypoglycemic effect, both in intact animals and in animals with experimental diabetes mellitus. RU-254 also reduces the level of glycated hemoglobin upon chronic administration, slightly decreases the activity of DPP-4, and increases the average number of Langerhans islets in the pancreas. Pharmaceutical drug formulation of RU-254 was developed and investigated for pharmacokinetic, pharmacodynamic, and toxicological properties. The dosage form of the drug under the name limiglidol (compound RU-254, diabenol) was evaluated in the full cycle of clinical studies that confirmed the safety, tolerability, and prominent antidiabetic properties of the drug.
Research Institute for Physical and Organic Chemistry, South Federal University, Russia
Olga N. Zhukovskaya
Research Institute for Physical and Organic Chemistry, South Federal University, Russia
*Address all correspondence to: pvassiliev@mail.ru
1. Introduction
The history of drug discovery for the treatment of diabetes mellitus was and still is strongly determined by achievements in the field of fundamental medicine. Initially, the role of the pancreas and islets of Langerhans in the development of this pathology was proved; later, the structure of insulin, insulin receptor, and glucose transporters was deciphered; the role of the liver glycogenolysis and gluconeogenic enzymes, contributing to increased glucose output and hyperglycemia, was established; molecular mechanisms for the development of insulin resistance, the importance of the incretin system and Na+/glucose transporters in the kidneys, and intestinal α-glucosidase were revealed, which led to the introduction of novel antidiabetic drugs into clinic [1, 2, 3, 4].
The basis of insulin resistance at the cellular level primarily resides in the disruption of insulin signaling pathway at the level of the insulin receptor and insulin receptor substrate (IRS) proteins. The underlying mechanism of this phenomenon is impaired phosphorylation of serine amino acid residues, catalyzed by a number of intracellular protein kinases. The muscles, liver, and adipose tissue are the primary target organs of concern for the development of insulin resistance [5]. It was established that the severity of insulin resistance correlates, first of all, with intracellular lipid accumulation [6]. It is intracellular lipids that hamper signal transmission from the insulin receptor and cause a decrease in insulin-dependent glucose uptake. The pivotal role of AMP-dependent protein kinase (AMPK), which is an energy “sensor” of the cell, is also established, since AMPK through TORCI, the first mTOR-based protein complex, serves as a metabolic switch between catabolic and anabolic processes of the cell. Metformin is a biguanide derivative, which is the first-line drug for the treatment of type 2 diabetes. In 2001, it was shown that the molecular mechanism of its action is at least in part mediated by AMPK [7]. It is believed that indirect activation of AMPK by metformin-induced Ser172 phosphorylation determines its pleiotropic effects [8].
At the same time, it is important to note that course of type 2 diabetes mellitus characterized by several consecutive phases. It begins with primary insulin resistance and compensatory hyperinsulinemia with the subsequent development of β-cell dysfunction, thus creating the need for administration of insulin secretagogues or insulin formulations at the late stages of the disease [9, 10, 11].
Given that the previous works described the insulinogenic effect of the antihelminthic drug mebendazole [12], which can be considered as a new scaffold (2-aminobenzimidazole or cyclic guanidine) that exhibits an insulinogenic effect, we performed an experimental study of the novel cyclic guanidine derivatives, designed by introduction of additional fused cycle (imidazole, dihydroimidazole, and tetrahydropyrimidine).
The synthesis of novel 2-aminobenzimidazole (AmBI) [13, 14] derivatives and fused benzimidazole derivatives was carried out, including N9-imidazo[1,2-a]benzimidazoles (N9-ImBI) [15, 16, 17], N1-imidazo[1,2-a]benzimidazoles (N1-ImBI) [18, 19], N9-2,3-dihydroimidazo[1,2-a]benzimidazoles (N9-DhImBI) [20, 21], N1-2,3-dihydroimidazo[1,2-a]benzimidazoles (N1-DhImBI) [18, 19], and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles (PrmBI) [22, 23, 24].
In order to identify the most promising antidiabetic substances using IT Microcosm [25, 26] and PASS computer systems [27, 28], a step-by-step detailed in silico analysis of the hypoglycemic properties of the new compounds was carried out. Programs DruLiTo [29] and QikProp [30] were employed to assess key ADME properties and characteristics.
Hypoglycemic effect of the newly obtained derivatives was initially studied in rats upon intraperitoneal administration at a dose of 50 mg/kg. Blood sampling was carried out 4 hours after treatment with test compounds. Blood glucose concentration was determined with the glucose oxidase method using a commercial Glucose FKD kit [31]. The ratio of glucose concentrations in the blood plasma of the experimental and control group animals served as an indicator of hypoglycemic activity [32].
It was found that among condensed benzimidazole derivatives, a number of substances exceeded hypoglycemic activity of metformin, which served as a reference drug.
2.1 In silico study
IT Microcosm [25, 26] and PASS [27, 28] computer systems were employed to determine the most promising chemical class of compounds. A training set of known hypoglycemic drugs and a library of tested benzimidazole derivatives were subjected to a consensus prediction of the level of hypoglycemic activity. The average informativity coefficient KPr was calculated and used as a metric for comparison of AmBI, N9-ImBI, N1-ImBI, N9-DhImBI, N1-DhImBI, and PrmBI derivatives. KPr value ranges from 0 for inactive compounds to 5 for highly active compounds.
According to value of KPr, the potential of benzimidazole derivatives classes as sources of substances with hypoglycemic activity decreases in the following order: N9-DhImBI (KPr = 4.50) > PrmBI (KPr = 4.25) > AmBI (KPr = 2.50) > N1-ImBI (KPr = 2.00) > N1-DhImBI (KPr = 1.25) > N9-ImBI (KPr = 0.25) [33].
Thus, it was shown that N9-2,3-dihydroimidazo[1,2-a]benzimidazole and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazole derivatives have the most promising blood glucose lowering activity. That is, these tricyclic structures containing embedded guanidine group turned out to be more active than 2-aminobenzimidazole derivatives.
Subsequently, employing substructural analysis [34] and analysis via median [35] and supremal [36] estimates, the class of N9-2,3-dihydroimidazo[1,2-a]benzimidazoles was selected as the most promising for the development of hypoglycemic compounds (Figures 1 and 2). It was shown that this scaffold is more preferable than 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazole.
Figure 1.
Informativity coefficients describing the influence of basic benzimidazole structure on high hypoglycemic activity level (according to the substructural analysis).
Figure 2.
Supremal evaluations of the effect of basic benzimidazole structure on high hypoglycemic activity level.
Substructural analysis [34] of the level of hypoglycemic activity among the N9-2,3-dihydroimidazo[1,2-a]benzimidazole derivatives allowed us to reveal a chemical feature (substituent) that largely determines high hypoglycemic activity—diethylaminoethyl substituent at the N9 atom of the N9-DhImBI scaffold.
According to the frequency analysis of physicochemical parameters [37] of experimentally studied derivatives of N9-DhImBI scaffold, a significant feature of high hypoglycemic activity was revealed—a charge on the internal imidazole cycle of the condensed system, namely, Q(Imid1)cs ≥ −0.109, which is a characteristic for compound RU-254 (diabenol).
Taken together, the results of a complex consensus in silico analysis of the hypoglycemic activity of six classes of benzimidazole derivatives revealed 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole dihydrochloride (RU-254, diabenol) as the most promising highly active compound.
To assess the feasibility of a further study of the pharmacological properties of compound RU-254, we calculated parameters of drug-likeliness and ADME properties (absorption, distribution, metabolism, excretion) for RU-254 and reference antidiabetic drugs metformin and glibenclamide.
Using the DruLiTo program [29], it was found that diabenol satisfies the boundary conditions of all eight drug-likeliness filters, while metformin and glibenclamide correspond only for two of them.
Water solubility, serum albumin binding parameters, cellular permeability, and absorbability through the gastrointestinal tract for the three aforementioned substances were calculated with QikProp program [30]. A comparative analysis of the obtained characteristics showed that water solubility and the degree of binding to serum albumin of diabenol are higher than that of glibenclamide and lower than that of metformin. Indicators of bioavailability and absorbability through the gastrointestinal tract in diabenol are higher than that of glibenclamide and metformin. Thus, in terms of the total pharmacokinetic characteristics calculated in the QikProp program, diabenol is superior to metformin and glibenclamide. It should be noted that the calculated values of pharmacokinetic parameters of all three compounds are in the ranges that are recognized as appropriate for drug molecules.
Summarizing the results of the evaluation of ADME properties obtained using two computational approaches, it can be argued that diabenol in regard of its calculated drug-like and pharmacokinetic characteristics is not inferior to metformin and glibenclamide and is a very promising substance for performing advanced preclinical studies.
2.2 Synthesis
Synthesis of 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole dihydrochloride (RU-254, diabenol) is readily realized through condensation of 2-amino-1-diethylaminoethylbenzimidazole with an excess of dibromoethane and subsequent transformation of the resulting of 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole dihydrobromide to the base and the desired dihydrochloride [21].
Example. A stirred suspension of 69.6 g (0.3 mol) of 2-amino-1-diethylaminoethylbenzimidazole (I) in 104 ml (1.2 mol) of dibromoethane is gently heated in a glycerin bath. At 60–70°C, the initial amine dissolves completely, and at 100–105°C, an exothermic cyclization reaction occurs (the bath is set aside at the beginning), accompanied by strong boiling up of the reaction mass while temperature rises to 140°C and a heavy colorless precipitate begins to form. After 5–7 minutes, the reaction virtually ends, and, in order to complete it, the mixture is heated for an additional 20 minutes at 140–145°C. After that, 80 ml of DMF are added to the thick mass with vigorous stirring, and the mixture is heated for another 10–15 minutes. Cooling to 20–25°C, filtering the precipitate, and washing with DMF (3 × 20 ml) and acetone (3 × 25 ml) afford 106 g of dihydrobromide (II) in 84% yield. The latter is dissolved in 230 ml of water and boiled for 10 minutes with 3–5 g of activated carbon. Carbon is filtered off, and the filtrate after cooling is brought to pH 10 with 40% sodium hydroxide solution. The light yellow oil (III) which separates on the surface is extracted with toluene. The toluene extracts are washed with water and dried with anhydrous potassium carbonate. The desiccant is filtered off and washed with toluene. Combined toluene fractions are acidified by gradual addition of a saturated solution of hydrogen chloride in 2-propanol to pH 1. The heavy colorless precipitate of dihydrochloride (IV) is filtered off after 4–5 hours at 20–25°C, washed with acetone, and dried at 100–110°С for 2–3 hours to a constant weight. Yield is 75 g (90.9%) from dihydrobromide (III) and 75% from the initial amine (II). The crude product can be recrystallized from 2-propanol to pharmacopeia grade purity.
2.3 Preclinical studies
Diabenol had a pronounced hypoglycemic effect and antihyperglycemic activity in carbohydrate tolerance tests performed on white outbred rats and rabbits. The compound studied showed a marked decrease of glycemia in animals with impaired glucose tolerance (in rats with severe streptozotocin diabetes and insulin resistance syndrome), in rats with alloxan diabetes, and in rabbits with acute insulin deficiency, induced with administration of anti-insulin guinea pig serum. In experiments on pancreatomic dogs, diabenol did not reduce blood glucose but enhanced the hypoglycemic effect of exogenously administered insulin [38, 39, 40], thus confirming insulin-mediated mechanism of action.
Detailed study of antidiabetic action revealed not only pancreatotropic but also extrapancreatic components of diabenol action. Its pancreatotropic effect is determined by the enhancement of phase 1 insulin secretion, especially in glucose-stimulated conditions (Figures 3 and 4).
Figure 3.
Effect of diabenol (10 mg/kg, intravenously) in blood insulin levels during glucose tolerance test (1 g/kg) in cats.
Figure 4.
Effect of diabenol (10 mg/kg, intravenously) on the basal portal vein blood glucose levels in cats [38].
Diabenol increases the insulin-dependent glucose uptake in muscles of rat diaphragm. Under conditions of alloxan-induced diabetes in rats, diabenol restored liver glycogen content and glycolysis rate and inhibited glycogenolysis in insulin-dependent organs and tissues (liver, striated muscles) while having no significant effect on these parameters in kidneys, which are insulin-independent organs [38].
It could be assumed that increased insulinotropic effect of diabenol is associated with a possible incretinomimetic effect. Studies [41] showed the ability of diabenol to inhibit the incretin-degrading DPP-4 enzyme, leading to a modulation of the insulin response. In our studies, diabenol also inhibited DPP-4, but in substantially higher concentrations (IC50 1.35–2.05 mM), which cannot be achieved in the animal’s body. Along with that, a 28-day administration of diabenol to rats with streptozotocin-induced diabetes was found to slightly and statistically insignificantly decrease the plasma activity of DPP-4 [42], which could be attributed to the action of its metabolites.
Long-term administration of diabenol to streptozotocin-nicotinamide-induced diabetic rats allowed us to obtain interesting and valuable results. Oral administration of diabenol in a dose of 25 mg/kg for 4 weeks reduced blood glucose levels and volume of consumed liquid by more than 2 times, and level of glycated hemoglobin by 2.2%, and increased the content of C-peptide [43]. Moreover, diabenol administration resulted in a significant increase in the average number of islets of Langerhans in the splenic region of the pancreas and a significant increase in the area of the pancreatic β-cells (Table 1) [44].
Morphometric parameters of pancreatic islets in splenic region of the pancreas of streptozotocin-nicotinamide-induced diabetic rats after administration of diabenol for 21 days (M ± m) [44].
Statistically significant compared with the intact control group.
The studied compound did not affect the apoptosis index (fraction of caspase-3 positive cells) and the proliferation index (PCNA-positive and Ki-67-positive cells) of the endocrinocytes of Langerhans islets. That is, diabenol had a cytoprotective effect on the cells. These data confirm the possibility of increasing the synthetic activity of β-cells under the influence of diabenol [44].
Given the complex nature of type 2 diabetes mellitus and aiming to increase the effectiveness of antidiabetic therapy in clinical practice, combination drugs (fixed combinations) are actively used to simultaneously target several key pathogenesis factors of the underlying disease or its complications [7, 9]. The optimal ratios of diabenol with metformin (1:4) and glibenclamide (5:1) were determined in experiments on rats with streptozotocin-nicotinamide-induced diabetes. Administration of these fixed combinations proved to be effective in terms of key metabolic markers, including blood glucose level, dynamics of glycated hemoglobin reduction, C-peptide level, and recovery of pancreatic β-cells, and has a positive impact on carbohydrate metabolism—liver glycogen content and glycogenolysis [45].
A very important aspect of diabetes pathogenesis is the activation of lipid peroxidation, which facilitates development of β-cell dysfunction and peripheral insulin resistance [11]. In order to address this issue in clinical practice, combination therapy regimens for diabetes have begun to include an antioxidant, for example, lipoic acid [46]. At the first stage of our study, the direct effect of some antidiabetic agents on free radical processes was studied in vitro. It was established that diabenol is a scavenger of superoxide anion, hydroxyl, and peroxyl radicals; rosiglitazone is active only against the superoxide anion, gliclazide has an antiradical effect in experiments with DPPH, and metformin and glibenclamide were unable to interfere with these processes. At the same time, the established direct antioxidant properties of some studied drugs are difficult to be expected in vivo, since they require relatively high concentrations to exert antiradical activity in vitro [47, 48].
A further study [48] determined the optimal ratios for a combination of diabenol and lipoic acid (2.8: 1 and 5.6: 1). Its activity was studied in a streptozotocin-nicotinamide-induced diabetic rat model. It was established that this combination possesses a more pronounced antidiabetic effect than monotherapy with diabenol. The more important finding of this study is a significantly reduced content of lipid peroxidation products in the liver, pancreas, and kidneys. In the pancreas under streptozotocin intoxication conditions, β-cells were significantly preserved by the combined treatment with diabenol and lipoic acid.
It is known that diabetes is associated with the increased thrombogenic potential of the blood and impaired rheology properties [49]. This effect is attributed not only to hyperosmolarity of the blood due to hyperglycemia but also to an increased aggregation of platelets and red blood cells. Among the antidiabetic agents used in clinical practice, only gliclazide has a direct inhibitory effect on platelets [8]. For other drugs, a similar effect is observed only with prolonged therapy. Given the fact that diabetes increases the frequency of thrombosis events, we studied the effect of diabenol on aggregation properties of platelets and red blood cells and its influence on microcirculation in experimental diabetes.
It was established that diabenol, both in vitro and in the conditions of the whole organism, has an antiplatelet activity. Probably, the effect on functional activity of platelets is determined by the influence of diabenol on balance of prostacyclin and thromboxane A2 systems. Diabenol showed an antithrombogenic effect on the model of thrombosis of the carotid induced by electric current and in systemic adrenaline-collagen thrombosis, exceeding the activity of gliclazide [50, 51, 52].
Diabenol reduced the aggregability and increased the erythrocyte deformability in normal conditions and, more profoundly, in experimental diabetes. Using fluorescent probes, it has been shown that diabenol was able to increase electronegativity and reduces the microviscosity of the red blood cells membrane, which results in the increase in their deformability [53, 54, 55, 56].
Amelioration of thrombogenic potential and blood viscosity gives diabenol ability to enhance the survival of skin graft (a model of the diabetic foot) in both intact and alloxan-induced diabetic animals [57].
Toxicological study of the diabenol pharmaceutical substance and the dosage form (tablets containing 0.2 g of the active ingredient) involved acute and chronic toxicity, examination of cumulative properties, immunotoxicity, effects on carcinogenesis, and transplacental action. The therapeutic dose of the drug had no adverse effects. Subtoxic doses of diabenol lead to a sharp decrease in pancreatic β-cell secretion along with platelet hemorrhages.
Upon long-term administration of diabenol to low-cancer NMRI mice, transgenic HER-2/neu mice, and LIO rats with drinking water, no toxic or carcinogenic effect was observed. An interesting fact has been demonstrated, that is, in NMRI mice, diabenol delayed the development of age-related disorders of the extra function and increased the life span of animals. The drug inhibited the occurrence of spontaneous tumors, reduced the incidence of malignant lymphomas, and inhibited the onset and development of colon cancer induced with 1,2-dimethylhydrazine in rats. The authors of this study conclude that diabenol has an anticarcinogenic and geroprotective effect. Hence, both diabenol and metformin contain a guanidine group in their structure and exert experimentally proven antitumor effect and geroprotective activity [58, 59, 60].
The data on the pharmacokinetic study of diabenol established the values of the drug half-life and average retention time, which suggest that the substance undergoes significantly rapid elimination. The drug penetrates well into organs and tissues, especially in those with a high degree of vascularization. An important role in the processes of elimination of a compound is played by processes of its metabolism [61].
2.4 Clinical studies
Clinical studies of diabenol were conducted on 180 patients with type 2 diabetes. The drug was administered orally in solid dosage form (0.2 g tablets) 2 times a day. The study design was a randomized controlled comparative study of efficacy, tolerability, and safety. Glidiab (gliclazide) served as a reference drug. The course of diabenol administration ameliorated both fasting and postprandial hyperglycemia, reduced glycated hemoglobin level by 1.1% at the end of the third month, and increased postprandial insulin levels. Diabenol reduced platelet aggregation, increased erythrocyte deformability, and reduced their aggregability, thus normalizing coagulation hemostasis [62, 63].
Clinical and laboratory parameters of patients allowed to conclude that diabenol administered in a dose of 0.4 g per day for 3 months had no adverse or toxic effects [63].
Based on the studies performed, it can be stated that aminobenzimidazole is a universal privileged substructure that can be used as a source for development of novel antidiabetic agents. Introduction of structural modifications by means of transition to tricyclic structures led us to the identification of N9-2,3-dihydroimidazo[1,2-a]benzimidazole as an optimal scaffold, and in this chemical class of compounds, agents with high glucose lowering activity were identified.
As a result, RU-254, or diabenol, was developed as the most active compound. Both in the experimental and clinical settings, it restores insulin secretion and ameliorates peripheral tissue glucose uptake. Another important effect of diabenol that has been established experimentally and confirmed in clinical studies is a reduction of thrombogenic potential and viscosity of blood. It has been demonstrated that diabenol, much like the biguanide derivative metformin, exerts an anticarcinogenic and geroprotective effect in rodents.
Thus, a new cyclic aminobenzimidazole derivative, diabenol, containing a guanidine group, combines pharmacological effects characteristic for both biguanide derivatives (reduction of hyperglycemia and liver glycogenolysis, improved glucose tolerance, anticarcinogenic and geroprotective effects) and for sulfonylurea derivative gliclazide (restoring insulin secretion, antiplatelet, and antiradical activity). It is quite possible that all of the identified effects are not a manifestation of the multi-target action but are pleiotropic effects of diabenol.
References
1.Blaslov K, Naranda FS, Kruljac I, Renar IP. Treatment approach to type 2 diabetes: Past, present and future. World Journal of Diabetes. 2018;9:209-219. DOI: 10.4239/wjd.v9.i12.209
2.Dedov II, Shestakova MV. Diabetes Mellitus: Diagnosis, Treatment, Prevention. Moscow: Medical Information Agency; 2011. p. 808
3.Spasov AA, Chepurnova MV. Scientific approaches to the combination therapy of type 2 diabetes mellitus. Bulletin of Volgograd State Medical University. 2011;1:8-12
4.Spasov AA, Petrov VI, Chepliaeva NI, Lenskaya KV. Fundamental bases of search of medicines for therapy of a diabetes mellitus type 2. Vestnik Rossiĭskoĭ Akademii Meditsinskikh Nauk. 2013;2:43-49. DOI: 10.15690/vramn.v68i2.548
5.Tkachuk VA, Vorotnikov AV. Molecular mechanisms of insulin resistance. Diabetes Mellitus. 2014;2:29-40. DOI: 10.14341/DM2014229-40
6.Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, et al. Ectopic fat and insulin resistance: Pathophysiology and effect of diet and lifestyle interventions. International Journal of Endocrinology. 2012;2012:1-18. DOI: 10.1155/2012/983814
7.Steinberg GR, Kemp BE. AMPK in health and disease. Physiological Reviews. 2009;89:1025-1078. DOI: 10.1152/physrev.00011.2008
8.Siluk D, Kraliszan R. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia. 2002;7:1034-1037. DOI: 10.1007/s00125-002-0855-0
9.Ametov AS. Type 2 Diabetes. Problems and Solutions. Moscow: GEOTAR-Media; 2015. p. 280, p. 352
10.Ametov AS, Kondratyeva LV, Prudnikova MA. Metformin—More than the gold standard. In: Ametov AS, editor. Type 2 Diabetes. Problems and Solutions. Moscow: GEOTAR-Media; 2015. pp. 202-256
11.Balabolkin MI, Klebanova EM, Kreminskaya VM. Treatment of Diabetes Mellitus and Its Complications. Moscow: Medicine; 2005. pp. 288-304
12.Caprio S, Ray TK, Boden G, et al. Improvement of metabolic control in diabetic patients during mebendazole administration: Preliminary studies. Diabetologia. 1984;27:52-55
13.Anisimova VA, Koshchienko YV, Pyatin BM et al. The Method of Obtaining Derivatives of 2-Amino-1-Aminoalkylbenzimidazoles. USSR Authorship certificate №. 1149592. Bulletin of Inventions. 1984
14.Anisimova VA, Spasov AA, Kosolapov VA, et al. Synthesis and pharmacological activity of 3-(N,N-disubstituted)acetamide-1-R-2-aminobenzimidazolium chlorides. Khimiko-Farmatsevticheskii Zhurnal. 2012;46:6-10. DOI: 10.30906/0023-1134-2012-46-9-6-10
15.Anisimova VA, Simonov AM. 3-Acyl-substituted imidazo[1,2-a]benzimidazoles. Khimiya Geterotsiklicheskikh Soedinenii. 1976;1:121-125
16.Anisimova VA, Spasov AA, Kucheryavenko AF, et al. Synthesis and pharmacological activity of 2-(hetaryl)imidazo[1,2-a]benzimidazoles. Khimiko-Farmatsevticheskii Zhurnal. 2002;36:12-17
17.Simonov AM, Anisimova VA, Borisova TA. Preparation of imidazo[1,2-a]benzimidazole derivatives from 1-alkyl-, 1-aralkyl-2-iminobenzimidazoline-3-acetic acids and their esters. Khimiya Geterotsiklicheskikh Soedinenii. 1973;1:111-114
18.Anisimova VA, Zhukovskaya ON, Kuzmenko TA. Synthesis of benzimidazole derivatives and condensed systems based on it. In: Spasov AA, Petrov VI, Minkin VI, editors. Antidiabetic Potential of Benzimidazoles. Volgograd: VolgSMU; 2016. pp. 56-106
19.Spasov AA, Dudchenko GP, Voronkova MP. Antidiabetic properties of the diabenol compound. In: Spasov AA, Petrov VI, Minkin VI, editors. Antidiabetic Potential of Benzimidazoles. Volgograd: VolgSMU; 2016. pp. 151-166
20.Anisimova VA, Levchenko MV, Koshchienko YV, Pozharskiy AF. The method of obtaining 9-substituted 2,3-dihydroimidazo[1,2-a]benzimidazole or their salts. USSR Authorship certificate №. 952847. Bulletin of Inventions. 1982;31:126
21.Anisimova VA, Levchenko MV, Kovalev GV. Synthesis and pharmacological activity of some 2,3-dihydroimidazo[1,2-a]benzimidazoles and intermediate products of their synthesis. Khimiko-Farmatsevticheskii Zhurnal. 1987;21:313-319
22.Anisimova VA, Spasov AA, Tolpygin IE, Ogasov AA, Stepanov AV. Synthesis and pharmacological activity of N-aryloxyethyl-substituted 9H-2,3-dihydroimidazoyl and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles. Khimiko-Farmatsevticheskii Zhurnal. 2006;40:23-26
23.Anisimova VA, Tolpygin IE, Spasov AA. Synthesis and pharmacological activity of 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles. Khimiko-Farmatsevticheskii Zhurnal. 2012;46:3-8
24.Anisimova VA, Spasov AA, Kosolapov VA. Synthesis and pharmacological activity of 2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-N-acetic acids. Khimiko-Farmatsevticheskii Zhurnal. 2012;46:15-20
25.Vassiliev PM, Kochetkov AN. IT Microcosm. State Registration Certificate for Software Program 2011618547 (Russian); 2011
26.Vassiliev PM, Spasov AA, Kosolapov VA, Kucheryavenko AF, Gurova NA, Anisimova VA. Consensus drug design using IT microcosm. In: Gorb L, Kuz’min V, Muratov E, editors. Application of Computational Techniques in Pharmacy and Medicine. Dordrecht Netherlands: Springer Science + Business Media; 2014. pp. 369-431
27.Filimonov DA, Poroikov VV, Gloriozova TA, Lagunin AA. PASS: State Registration Certificate for Software Program 2006613275 (Russian); 2006
28.Filimonov DA, Poroikov VV. Prediction of the spectrum of biological activity of organic compounds. Rossiiskii Khimicheskii Zhurnal. 2006;50:66-75
29.Drug Likeness Tool (DruLITo) [Internet]. 2017. Available from: http://www.niper.gov.in/pi_dev_tools/DruLiToWeb/DruLiTo_index.html [Accessed: Jan 15, 2019]
30.QikProp: Rapid ADME Predictions of Drug Candidates [Internet]. 2017. Available from: https://www.schrodinger.com/QikProp [Accessed: Jan 15, 2019]
31.Severin SE, Solovyeva GA, editors. Workshop on Biochemistry: A Textbook. 2nd ed. Moscow: MSU; 1989. p. 509
32.Larsen SD, Connell MA, Cudahy MM, Evans BR, May PD, Meglasson MD, et al. Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: Discovery of a novel aminoguanidinoacetic acid antidiabetic agent. Journal of Medicinal Chemistry. 2001;44:1217-1230. DOI: 10.1021/jm000095f
33.Vassiliev PM, Spasov AA, Lenskaya KV, Poroikov VV, Filimonov DA, Anisimova VA. Planning of in silico screening and experimental study of hypoglycemic cyclic guanidine derivatives. Kuban Scientific Medicinal Bulletin. 2014;6(148):11-15
34.Vassiliev PM, Spasov AA, Lenskaya KV, Anisimova VA. Substructural analysis of the hypoglycemic activity of cyclic guanidine derivatives. Bulletin of Volgograd State Medical University. 2014;3(51):28-30
35.Lenskaya KV, Vassiliev PM, Spasov AA, Anisimova VA. Analysis of the prospects of chemical classes of cyclic guanidine derivatives with the method of median estimates. Vestn. Novosti Meditsinskoĭ Tekhniki. 2015;3:2-8. DOI: 10.12737/13202
36.Lenskaya KV, Vassiliev PM, Spasov AA, Anisimova VA. Analysis of the prospects of chemical classes of cyclic guanidines with the method of supremal assessment. Bulletin of Volgograd State Medical University. 2015;2(54):98-100
37.Lenskaya KV, Cheplyaeva NI, Vassiliev PM, Spasov AA, Anisimova VA. Frequency analysis of the dependence of hypoglycemic activity on the physicochemical parameters of cyclic guanidine derivatives. In: Proceedings of the XXth Anniversary Russian National Congress “Man and Drug”. Moscow; 2013. p. 372
38.Spasov AA, Dudchenko GP, Turchaeva AF, Kovalev SG. Development of hypoglycemic drugs with antiplatelet properties based on condensed benzimidazole derivatives. Bulletin of Volgograd State Medical University. 1995;1:33-36
39.Spasov AA, Gavrilova EE. Diabenol—A new antidiabetic agent with hemobiological properties. Bulletin of Volgograd State Medical University. 1997;3:47-51
40.Spasov AA, Yozhitsa IN, Bugaeva LI, Anisimova VA. Benzimidazole derivatives: Spectrum of pharmacological activity and toxicological properties (a review). Pharmaceutical Chemistry Journal. 1999;33:232-243. DOI: 10.1007/BF02510042
41.Zolotov NN, Kreminskaya VM. Dipeptidyl peptidase IV inhibiting agent and pharmaceutical composition based on it. Patent RU2485952. 2013
42.Spasov AA, Cheplyaeva NI, Lenskaya KV, Snigur GL. The effect of a limiglidol on DPP-4 and morphological features of pancreatic islets in streptozotocin diabetes model. Eksperimental’naia i Klinicheskaia Farmakologiia. 2015;78:8-12
43.Spasov AA, Voronkova MP, Snigur GL. An experimental model of type 2 diabetes mellitus. Biomedicine. 2011;3:12-18
44.Cheplyaeva NI. Pharmacological properties of the combination of hypoclycemic substance diabenol and α-lipoic acid [thesis]. Volgograd: Volgograd State Medical University; 2012
45.Chepurnova MV. Pharmacological properties of combined hypoglycemic substances on the basis of the drug diabenol [thesis]. Volgograd: Volgograd State Medical University; 2011
46.Evans JL, Goldfine ID. Alpha-lipoic acid: A multifunctional antioxidant that improves insulin sensitivity in patient with type 2 diabetes. Diabetes Technology & Therapeutics. 2000;2:401-413
47.Spasov AA, Kosolapov VA, Cheplyaeva NI. Antioxidant activity of oral hypoglycemic agents. Problems of Endocrinology. 2011;4:21-24
48.Spasov AA, Kosolapov VA, Cheplyaeva NI. Comparative characteristics of antioxidant properties of hypoglycemic agents diabenol and gliclazide. Eksperimental’naia i Klinicheskaia Farmakologiia. 2011;74:14-16
49.Morel O, Kossler L, Ohimann P. Diabetes and the platelets: Toward new therapentic paradigms for diabetic atherothrombosis. Atheroscherosis. 2010;2:367-376
50.Kucheryavenko AF, Spasov AA, Petrov VI, Anisimova VA. Antiaggregant activity of a new benzimidazole derivative. Bulletin of Experimental Biology and Medicine. 2014;156:796-798. DOI: 10.1007/s10517-014-2453-9
51.Kucheryavenko AF, Spasov AA, Smirnov AV. Antithrombotic activity of a new hypoglycemic compound limiglidole in mouse model of cell thrombosis. Bulletin of Experimental Biology and Medicine. 2015;159:41-43. DOI: 10.1007/s10517-015-2885-x
52.Spasov AA, Kucheryavenko AF, Chepurnova MV, Lenskaya KV. Antithrombotic activity of hypoglycemic agents. Regional Blood Circulation and Microcirculation. 2011;10:95-98
53.Degtyarev AN, Kucheryavenko AF, Spasov AA, Ostrovskiy OV. Benzimidazole derivatives as the basis for the creation of drugs that affect the rheological properties of blood. In: Proceedings of Actual Problems of Experimental and Clinical Pharmacology; May 1999; Saint-Petersburg. Saint-Petersburg: Politekhnika; 1999. p. 120
54.Degtyarev AN, Ostrovskiy OV, Shakhova NI, Anisimova VA. Evaluation of the corrective effect of new compounds, benzimidazole derivatives, with the “increased viscosity syndrome”. In: Proceedings of Actual Problems of Experimental and Clinical Pharmacology; May 1999; Saint-Petersburg. Saint-Petersburg: Politekhnika; 1999. p. 59
55.Spasov AA, Petrov VI, Anisimova VA. New hypoglycemic agent with hemorheological properties. In: Proceedings of IVth Russian Diabetological Congress; 19-22 May 2008; Moscow. Moscow; 2008. p. 336
56.Kucheryavenko AF, Spasov AA, Naumenko LV. The influence of new hypoglycemic agent limiglidol on the parameters of hemostasis in experimental diabetes. Problems of Endocrinology. 2015;61:51-56. DOI: 10.14341/probl201561151-56
57.Vasilyeva SV, Galenko-Yaroshevskiy VP, Khropova TN, Tegay AV, Uvarov AV. The effect of imidazobenzimidazole derivatives RU-185 and RU-254 on the viability of the skin graft. Bulletin of Experimental Biology and Medicine. 2002;2:90
58.Popovich IG, Zabezhinskiĭ MA, Anikin IV, Tyndyk ML, Spasov AA, Anisimov VN. Inhibition of 1,2-dimethylhydrazine-induced carcinogenesis in rat gut by the antidiabetic drug Diabenol. Voprosy Onkologii. 2004;50:562-566
59.Popovich IG, Zabezhinskiĭ MA, Egormin PA, Anikin IV, Tyndyk ML, Semenchenko AV, et al. Effect of antidiabetic drug diabenol on parameters of biological age, life span and tumor development in NMRI and HER-2/neu mice. Advances in Gerontology. 2004;15:80-90
60.Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, Anikin IV, Spasov AA, et al. Insulin in aging and cancer: Antidiabetic drug diabenol as geroprotector and anticarcinogen. The International Journal of Biochemistry & Cell Biology. 2005;37:1117-1129. DOI: 10.1016/j.biocel.2004.08.002
61.Spasov AA, Dudchenko GP, Smirnova LA, Gavrilova ES. Pharmacodynamic and pharmacokinetic properties of the compound RU-254. Bulletin of Volgograd State Medical University. 1999;5:26-34
62.Dedov II, Balabolkin MI, Spasov AA, Petrov VI. New domestic hypoglycemic agent with hemorheological properties—diabenol (clinical studies). In: Proceedings of IVth Russian Diabetological Congress; 19-22 May 2008; Moscow. Moscow; 2008. p. 268
63.Petrov VI, Spasov AA, Nedogoda SV, Voronkova MP. Clinical efficacy of the drug diabenol in type 2 diabetes mellitus. In: Spasov AA, Petrov VI, Minkin VI, editors. Antidiabetic Potential of Benzimidazoles. Volgograd: VolgSMU; 2016. pp. 451-464
Written By
Alexander A. Spasov, Pavel M. Vassiliev, Vera A. Anisimova and Olga N. Zhukovskaya
Submitted: 20 November 2018Reviewed: 29 January 2019Published: 25 February 2019
Open access peer-reviewed chapter
